Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Pharmaceutical Statistics
|
September 2, 2020
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies
Anh Nguyen Duc, Dominik Heinzmann, Claude Berge, et al.
Therapeutic Innovation & Regulatory Science
|
April 14, 2025
Futility Interim Analyses - A Plea for Simplicity
Gian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology
|
February 24, 2010
Multidimensional fitting for multivariate data analysis
Claude Berge, Nicolas Froloff, Ravi Kiran Reddy Kalathur, et al.
Advances in Therapy
|
October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies, Claude Berge, Axel Boehnke, et al.
The Lancet. Oncology
|
February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Andrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Circulation
|
March 15, 2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry
Philip Urban, Anthony H Gershlick, Giulio Guagliumi, et al.
Annals of Clinical and Translational Neurology
|
July 9, 2025
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis
Ludwig Kappos, Sean Yiu, Jason Reucassel, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
The Lancet. Haematology
|
May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Andrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Nature Medicine
|
August 20, 2025
AI-driven reclassification of multiple sclerosis progression
Habib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Pharmaceutical Statistics
|
September 2, 2020
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies
Anh Nguyen Duc, Dominik Heinzmann, Claude Berge, et al.
Therapeutic Innovation & Regulatory Science
|
April 14, 2025
Futility Interim Analyses - A Plea for Simplicity
Gian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology
|
February 24, 2010
Multidimensional fitting for multivariate data analysis
Claude Berge, Nicolas Froloff, Ravi Kiran Reddy Kalathur, et al.
Advances in Therapy
|
October 7, 2017
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies, Claude Berge, Axel Boehnke, et al.
The Lancet. Oncology
|
February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
Andrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Circulation
|
March 15, 2006
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry
Philip Urban, Anthony H Gershlick, Giulio Guagliumi, et al.
Annals of Clinical and Translational Neurology
|
July 9, 2025
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis
Ludwig Kappos, Sean Yiu, Jason Reucassel, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
The Lancet. Haematology
|
May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Andrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Nature Medicine
|
August 20, 2025
AI-driven reclassification of multiple sclerosis progression
Habib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Page
of 1